HCC surveillance (using regular hepatic US with/without AFP) increases the rate of detecting early-stage HCC, thereby resulting in patients receiving curative treatment and possibly improving survival outcomes (Im et al., 2019; Stravitz et al., 2008; Yang et al., 2011). This evidence concerns the gene AFP and hepatocellular carcinoma.